Sugi Predict

Sugi Predict / Targets / ITK

ITK

Tyrosine-protein kinase ITK/TSK · Q08881 · ITK on Sugi Atlas →

125,134 patent compounds predicted against ITK, 83,036 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL141010 SCHEMBL141010 1.00 19/20
SCHEMBL141011 SCHEMBL141011 1.00 19/20
SCHEMBL140481 SCHEMBL140481 0.78 19/20
SCHEMBL140482 SCHEMBL140482 0.78 19/20
SCHEMBL139966 SCHEMBL139966 0.81 18/20
SCHEMBL139967 SCHEMBL139967 0.81 18/20
SCHEMBL137557 SCHEMBL137557 0.77 18/20
SCHEMBL137558 SCHEMBL137558 0.77 18/20
SCHEMBL139630 SCHEMBL139630 0.64 18/20
SCHEMBL139632 SCHEMBL139632 0.64 18/20
SCHEMBL139891 SCHEMBL139891 0.81 17/20
SCHEMBL139892 SCHEMBL139892 0.81 17/20
SCHEMBL140356 SCHEMBL140356 0.80 17/20
SCHEMBL140357 SCHEMBL140357 0.80 17/20
SCHEMBL141238 SCHEMBL141238 0.75 17/20
SCHEMBL141239 SCHEMBL141239 0.75 17/20
SCHEMBL140465 SCHEMBL140465 0.73 17/20
SCHEMBL140466 SCHEMBL140466 0.73 17/20
SCHEMBL139131 SCHEMBL139131 0.71 17/20
SCHEMBL139132 SCHEMBL139132 0.71 17/20

Clinical trials — most relevant to ITK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis PHASE4NOT_YET_RECRUITING
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway PHASE4COMPLETED
Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK PHASE3COMPLETED
Study of TS-1 or TS-1 + PSK for Gastric Cancer Patients PHASE3UNKNOWN
Resection+Highly Purified CTL Versus Resection Alone for HCC PHASE3UNKNOWN
Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma PHASE2/PHASE3UNKNOWN
CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT. PHASE1/PHASE2UNKNOWN
First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC PHASE2UNKNOWN
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma PHASE2ACTIVE_NOT_RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
Protein Tyrosine Kinases (PTK) in Multiple Myeloma PHASE2COMPLETED
A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma PHASE2UNKNOWN
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer PHASE2RECRUITING
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy PHASE2RECRUITING
Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant PHASE1/PHASE2UNKNOWN
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer PHASE1/PHASE2COMPLETED
Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies PHASE1/PHASE2COMPLETED
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors PHASE2RECRUITING
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma PHASE1COMPLETED
A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors PHASE1COMPLETED
FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers PHASE1RECRUITING
A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors PHASE1UNKNOWN
Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer nanACTIVE_NOT_RECRUITING
Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms nanWITHDRAWN
RT201(Tumor Antigen-specific Macrophage Tumor Vaccine) nanUNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Optimizing Cytokine-Induced Killer Cells in Glioblastoma Patients nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a ITK binder may also engage these)

ProteinNameSimilarity
TXK Tyrosine-protein kinase TXK 1.000 landscape →
P35991 — 1.000 P35991 →
Q03526 — 1.000 Q03526 →
TEC Tyrosine-protein kinase Tec 0.998 landscape →
P42682 — 0.996 P42682 →
BTK Tyrosine-protein kinase BTK 0.996 landscape →
P24604 — 0.995 P24604 →
Q0VBZ0 — 0.995 Q0VBZ0 →
Q8JH64 — 0.995 Q8JH64 →
P41241 — 0.994 P41241 →
FRK Tyrosine-protein kinase FRK 0.993 landscape →
P32577 — 0.993 P32577 →
CSK Tyrosine-protein kinase CSK 0.992 landscape →
P41239 — 0.991 P41239 →
P00526 — 0.991 P00526 →
Q60629 — 0.990 Q60629 →
P00528 — 0.990 P00528 →
Q922K9 — 0.990 Q922K9 →
P63185 — 0.989 P63185 →
Q64434 — 0.989 Q64434 →
BMX Cytoplasmic tyrosine-protein kinase BMX 0.989 landscape →
P42690 — 0.989 P42690 →
Q62662 — 0.989 Q62662 →
Q9V9J3 — 0.988 Q9V9J3 →
Q54Y55 — 0.988 Q54Y55 →
P31693 — 0.988 P31693 →
O13147 — 0.987 O13147 →
P42686 — 0.987 P42686 →
P25020 — 0.987 P25020 →
FGR Tyrosine-protein kinase Fgr 0.987 landscape →